Table 5.
Multivariate cox regression analysis of CKD stage 3 or higher and spontaneous remission
| Variable | CKD stage 3 or higher | Spontaneous remission | ||
|---|---|---|---|---|
|
|
|
|||
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Age | 1.084 (0.987–1.191) | 0.091 | 1.069 (1.009–1.133) | 0.024 |
| Sex, male | 0.493 (0.065–3.752) | 0.494 | 0.470 (0.166–1.333) | 0.156 |
| Diabetes mellitus | 1.542 (0.203–11.709) | 0.676 | 3.217 (0.519–19.956) | 0.210 |
| Hypertension | 1.074 (0.145–7.951) | 0.944 | 0.202 (0.043–0.956) | 0.044 |
| eGFR | 0.975 (0.945–1.006) | 0.110 | 0.998 (0.979–1.018) | 0.844 |
| UPCR | 1.108 (0.914–1.344) | 0.298 | 1.054 (0.807–1.376) | 0.699 |
| Serum albumin | 0.412 (0.062–2.719) | 0.357 | 1.656 (0.488–5.617) | 0.418 |
| Anti-PLA2R ab(+) | 13.926 (1.385–140.034) | 0.025 | 0.135 (0.026–0.689) | 0.016 |
CKD stage 3, defined as eGFR < 60 mL/min/1.73 m2; spontaneous remission, partial or complete remission without immunosuppressant.
Anti-PLA2R ab(+), anti-phospholipase A2 receptor antibody; CI, confidence interval; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HR, hazard ratio; UPCR, urine protein/creatinine ratio.